At a glance
| Brand | Cetrotide |
|---|---|
| Target | Pituitary GnRH receptor |
| Main role | Prevents premature LH surges |
| Setting | Controlled ovarian stimulation |
| Delivery | Subcutaneous injection |
| Initial hormone flare | Not expected with receptor antagonism |
Overview
Cetrorelix is used by fertility specialists alongside medicines that stimulate ovarian follicle growth. Its job is to suppress the pituitary signal that could otherwise trigger ovulation before the planned egg-retrieval procedure. This distinction explains why a drug that temporarily lowers reproductive hormone signaling can support fertility treatment. The approved product is a subcutaneous injection, and its use is tied to ultrasound and hormone monitoring during a particular cycle. Pregnancy outcomes depend on the entire treatment pathway, including ovarian reserve, embryo development and other infertility factors, rather than on cetrorelix alone.
How it works
Cetrorelix competitively blocks gonadotropin-releasing hormone receptors on pituitary cells. This promptly reduces LH secretion and also affects FSH release. Unlike a GnRH agonist, it does not first stimulate a surge of pituitary hormones before suppression develops. The inhibition is reversible after treatment stops. In ovarian stimulation, externally supplied gonadotropins continue supporting follicle growth while the antagonist helps prevent an untimely endogenous LH surge.
Why suppress LH during fertility treatment?
A premature LH surge can disrupt the timing of egg maturation and retrieval. Cetrorelix inhibits that surge while ovarian-stimulation medicines support the follicles. It does not replace follicle-stimulating treatment or the separate intervention selected to trigger final egg maturation.
Supporting sources [1]
What supports its clinical use?
Randomized phase III research compared cetrorelix with established GnRH-agonist protocols during assisted reproduction. These studies, together with the prescribing-information trials, support control of premature LH surges. Their findings concern defined stimulation cycles, not improved natural fertility or treatment of low sex hormones outside that setting.
Allergy and ovarian-stimulation risks
Hypersensitivity, including serious systemic reactions, can occur. The label contraindicates treatment in pregnancy, lactation and severe renal impairment, and in patients with specified peptide-hormone or ingredient allergies. Ovarian hyperstimulation syndrome remains a concern within the overall stimulation cycle, requiring assessment by the treating fertility service.
Supporting sources [1]
Is cetrorelix the same as an ovulation trigger?
No. Cetrorelix suppresses the signal that could cause early ovulation; a trigger treatment has a different purpose later in the cycle. The timing of these separate steps is clinically consequential. Approved fertility use does not establish cetrorelix as a general hormone-balancing or anti-aging treatment.
Supporting sources [1]
Reading this profile
Jurisdiction: United States; indications and availability vary by formulation and country.. Molecular class: Synthetic decapeptide GnRH receptor antagonist.
This profile was written with AI-assisted research and checked against the linked sources. It has not been represented as a clinician’s review. Evidence summaries describe the cited studies and products; they do not establish that a separately purchased preparation is equivalent.
Sources & references
Follow the original material. Product labels define specific formulations and uses; trial registration describes a study and does not by itself establish benefit.
- Cetrorelix acetate — current US prescribing information ↗Regulatory source · Checked 2026-10-27
- Ovarian stimulation with HMG: randomized phase III comparison of cetrorelix and buserelin ↗Original research · Checked 2026-10-27